News

Serina Therapeutics Responds to FDA for SER-252 Drug Approval

Serina Therapeutics Responds to FDA for SER-252 Drug Approval

Serina Therapeutics Moves Forward with SER-252 Program

Serina Therapeutics, Inc. is making strides in its quest to develop SER-252, a novel treatment targeting advanced Parkinson's disease. Recognized on the NYSE American under the ticker SER, Serina is taking significant steps following the submission of a complete response to the FDA regarding a clinical hold. This letter was initially prompted due to specific inquiries about the formulation excipient in their drug application.

FDA Clinical Hold and Resolution Efforts

Recently, the U.S. Food and Drug Administration (FDA) issued a clinical hold on Serina's Investigational New Drug (IND) application for SER-252. The hold arose following the need for additional clarity on the formulation excipient used in the drug. In response, Serina worked diligently to compile a comprehensive data package to address the Agency's concerns.

Key Components of the Response

The complete response submitted by Serina includes crucial information supporting the use of trehalose as a subcutaneous excipient. This data encompasses a comparison with other approved products that feature trehalose and insights from nonclinical analyses. Moreover, a revised research protocol is proposed to initiate the single ascending dose (SAD) phase of the SER-252-1b trial, anticipating to take off in the first quarter of 2026.

Importance of Continued Engagement with the FDA

Steve Ledger, CEO of Serina Therapeutics, expressed the company's commitment to addressing the FDA’s questions thoroughly. The engaging dialogue with the Agency is critical as they advance towards initiating the registrational study for SER-252.

Global Start-Up Initiatives for Clinical Trials

Despite the clinical hold, Serina has not paused its global initiatives for the SER-252 trial. The company remains active in site start-up activities across various regions, including Australia, where they have garnered substantial support from local investigators and the Parkinson’s community. Such groundwork is pivotal in ensuring robust participation for the planned trial.

Anticipated Milestones and Future Directions

Serina aims to have its first patient enrolled by early 2026, contingent upon receiving the necessary approvals. This milestone will be a significant step towards demonstrating the potential of SER-252 in providing much-needed therapeutic options for those suffering from advanced Parkinson's disease. The company's strategic preparations also include obtaining regulatory and ethical approvals, aligning their goals with patient needs.

Understanding Serina’s Innovative POZ Platform

At the heart of Serina Therapeutics' development strategy lies its proprietary POZ Platform, a cutting-edge drug optimization technology. This platform utilizes poly (2-oxazoline), a synthetic, water-soluble polymer designed to enhance the efficacy and safety of drugs delivered through subcutaneous injections. The benefits of this technology are especially pertinent for drugs that have previously faced limitations due to adverse pharmacokinetic profiles, including toxicity and short half-lives.

Diverse Applications and Future Collaborations

Serina’s POZ platform holds promise across a variety of therapeutic applications, and the company is enthusiastic about potential out-licensing or co-development partnerships. Their agreement with Pfizer, Inc. serves as a testament to the platform's versatility in lipid nanoparticle drug delivery systems.

Insights into SER-252 and Its Potential

SER-252 is an investigational therapy designed to provide continuous dopaminergic stimulation (CDS), aiming to alleviate symptoms associated with Parkinson's disease. Preclinical data suggest that this treatment could minimize common side effects such as skin reactions, often associated with similar therapies, enhancing patient comfort and adherence.

Frequently Asked Questions

What is SER-252?

SER-252 is an investigational drug developed by Serina Therapeutics aimed at treating advanced Parkinson's disease.

What challenges did Serina face with the FDA?

The FDA placed a clinical hold on Serina’s IND application for SER-252 due to questions about the formulation excipient.

What is the POZ Platform?

The POZ Platform is Serina's proprietary technology that enhances the efficacy and safety profiles of various drug modalities.

What are the anticipated developments for SER-252?

Serina anticipates starting the single ascending dose phase of the SER-252-1b trial in early 2026, pending FDA approvals.

Where is Serina Therapeutics headquartered?

Serina Therapeutics is based in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 45

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 23

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 92

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 0

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL SunPower Global Teams Up with Energia Italia for Solar Expansion

Updated Category News Views 313

TCL SunPower Global and Energia Italia Join Forces TCL SunPower Global is thrilled to unveil a new strategic partnership with Energia Italia, designed to significantly enhance the availability of advanced solar technology. As a renowned distributor in the residential and commercial solar markets, Energia Italia will take on the responsibility of providing Italian...

Continue Reading
AHAM Challenges Colorado's Appliance Labeling in Court

Updated Category News Views 200

AHAM Takes Legal Action Against Appliance Labeling Law The Association of Home Appliance Manufacturers (AHAM) has filed a federal lawsuit in response to a new appliance labeling law in Colorado. This law specifically mandates that gas stoves display a warning label concerning alleged health risks. AHAM alleges that this directive infringes upon First Amendment rights,...

Continue Reading
Impact BioMedical Inc. Sets Price for Its Initial Public Offering

Updated Category News Views 63

Impact BioMedical Inc. Pricing for Initial Public Offering Announced Impact BioMedical Inc. (NYSE: IBO) has officially revealed the pricing details for its initial public offering, establishing itself as a significant presence in the healthcare and wellness sectors. The company plans to offer 1,500,000 shares of its common stock at a public offering price of $3.00 per...

Continue Reading
Local Bounti Navigates NYSE Compliance Notice, Eyes Growth

Updated Category News Views 151

Local Bounti Faces NYSE Compliance Challenge Local Bounti Corporation (NYSE: LOCL), a pioneer in innovative indoor agriculture, has recently received an important notice from the New York Stock Exchange (NYSE). The notice highlights that the company is currently not meeting certain listing standards set by the NYSE. This notification pertains to the Minimum Market...

Continue Reading
SCWorx Expands Partnership: Three-Year Renewal and Growth

Updated Category News Views 154

SCWorx Strengthens Healthcare Partnerships with Renewed Agreement New York, NY — In a significant move, SCWorx Corp. (NASDAQ: WORX), known for its innovative healthcare data management solutions, has successfully renewed its agreement with a vital healthcare partner for another three years. This decision marks a substantial endorsement of the value SCWorx delivers, as...

Continue Reading